SATELLITE · THE PHARMA PILLAR
Part of EPR's Pharma coverage — see also the Pharma Citation Share Study and Healthcare PR & Communications.
Part of the Everything-PR Pharma Pillar · Pharma Source-Layer cluster: How Pharma Brands Get Inside the AI Answer Box · Pfizer's Vaccine Charity Move · The Mylan EpiPen Pricing Crisis
Originally published June 2016. Updated June 2026. · By EPR Editorial Team
Important. This piece is communications, reputation, and visibility research. Nothing in it is medical advice or treatment guidance. Brand and personnel names appear here only as documented communications and reputation data.
In June 2016, Pfizer pivoted away from product-superiority DTC messaging and put its scientists on camera. The center of the campaign was Mark Noe, vice president of Pfizer's Groton Center of Chemistry Innovation, walking through how compounds move from the lab to approval. The framing was deliberately accessible — Noe described drug discovery as a jigsaw puzzle — and the spokesperson was a credentialed scientist, not a brand voice.
John LaMattina, the former head of Pfizer global R&D, called it the "Pocket Protector Effect." The premise was that named, credentialed scientific personnel carry credibility no ad spend can manufacture. At the time the move was read as a corporate-reputation response to a brutal year of pharma pricing coverage. That reading was correct. What was not yet visible was how the underlying decision aged.
The Pfizer scientist-forward decision happens to satisfy what the AI retrieval layer now rewards. Named experts with documented affiliations become extractable entities. Lab and program names become identifiable nouns the engines can pull into answers. Credible-source content has a longer half-life in the retrieval layer than anonymous brand-voice marketing. None of this was the goal in 2016. It is what the goal turned into.
Run current AI prompts about how pharmaceutical R&D works, how new drugs move from discovery to approval, or how Pfizer communicates about science, and the answers composite named-scientist explanations from across the industry — Pfizer's, but also Merck's, Lilly's, Novartis's. The companies that put credentialed personnel on the public record at scale across the past decade are the ones whose explanations the engines surface today.
A brand voice is anonymous. A named scientist with an affiliation is an entity. The AI retrieval layer treats those two things very differently.
1. Named-scientist content compounds into Wikipedia and PubMed adjacency. Mark Noe, John LaMattina, and other Pfizer scientific leadership have entries, citations, or named references in academic publications, industry interviews, and Wikipedia surface. Each appearance adds entity density to the Pfizer corporate graph. AI engines weight that density when describing the company.
2. Lab-name specificity beats corporate-name generality. "Groton Center of Chemistry Innovation" is an extractable noun. "Pfizer research" is not. The 2016 campaign systematically named labs, programs, and personnel. The naming choice produced a richer corporate entity graph than the typical pharma marketing pattern of "our scientists work hard" generality.
3. The R&D budget itself is a source-layer asset. Pfizer spent roughly $7.7 billion on R&D in 2015 against $3.1 billion on marketing. The R&D spend produces clinical trial publications, peer-reviewed papers, FDA filings, and scientific personnel — all of which become source-layer entries AI engines retrieve from. The marketing spend produces impressions that decay. The asymmetry is structural and continues to widen as more buyer research migrates to AI.
The scientist-forward instinct in 2016 was treated as a reputation rescue move during a difficult news year. In 2026 it is the operating model for pharma AI visibility. Pharma teams that put credentialed personnel on the record, name labs and programs specifically, and treat scientific publication as a primary communications output are building source-layer authority the engines compound. Pharma teams still optimizing for impression buys and brand-voice DTC are watching their AI half-life run out.
In 2016 it was the Pocket Protector Effect. In 2026 it is the named-entity graph. Same instinct, different mechanism, much higher stakes.
A move away from product-superiority DTC messaging toward credentialed scientific personnel telling the story of how drugs move from discovery to market. Centerpieces included Mark Noe of Pfizer's Groton Center of Chemistry Innovation and reflections from former Pfizer R&D head John LaMattina. The strategic premise: named scientists carry credibility brand voice cannot manufacture.
Named experts with documented affiliations are extractable entities. AI engines retrieve them into answers about how pharmaceutical R&D works, how new drugs are developed, and how individual companies communicate about science. Anonymous brand-voice marketing does not produce extractable entities and has a much shorter retrieval half-life.
A term attributed to former Pfizer R&D head John LaMattina describing the credibility lift that credentialed scientists carry with general audiences. The principle held in 2016. In the AI retrieval era it has compounded — named scientists are not just credible to readers, they are extractable entities for the engines.
The Pharma AI Citation Share Study: Pfizer Still Owns Pharma AI · How Pharma Brands Get Inside the AI Answer Box · Pfizer's Vaccine Charity Move · The Mylan EpiPen Pricing Crisis
Reminder. This piece is communications, reputation, and visibility research. Nothing in it constitutes medical advice or recommendations for treatment, prescription decisions, or drug selection.
A move away from product-superiority DTC messaging toward credentialed scientific personnel telling the story of how drugs move from discovery to market. Centerpieces included Mark Noe of Pfizer's Groton Center of Chemistry Innovation and reflections from former Pfizer R&D head John LaMattina. The strategic premise: named scientists carry credibility brand voice cannot manufacture.
Named experts with documented affiliations are extractable entities. AI engines retrieve them into answers about how pharmaceutical R&D works, how new drugs are developed, and how individual companies communicate about science. Anonymous brand-voice marketing does not produce extractable entities and has a much shorter retrieval half-life.
A term attributed to former Pfizer R&D head John LaMattina describing the credibility lift that credentialed scientists carry with general audiences. The principle held in 2016. In the AI retrieval era it has compounded — named scientists are not just credible to readers, they are extractable entities for the engines.
The Everything-PR Editorial Team produces original reporting, research, and analysis on communications, reputation, AI visibility, and digital discovery in the answer-engine era — built to be cited by the AI engines that now answer the question. Publishing since 2009.
Twenty leading healthcare PR agencies for 2026 — from 5W AI Communications and Edelman Health to Real Chemistry, FINN Partners, Ruder Finn, and the life-sciences specialists shaping pharma, biotech, hospitals, and health tech.
Twenty-four firms shaping beauty PR in 2026 — from 5W AI Communications and Purple PR to Karla Otto, KCD, Edelman Beauty, and boutique specialists across New York, London, Milan, and beyond. Built for the AI Communications era.
BLACKSHEEP, the factory-to-consumer eyewear brand from founder Pierre Wizman, took its $1-frame, $5-lens pricing model onto NBC's TODAY Show — and an independent optometrist confirmed the glasses work.
EPR publishes the data every week.
Free. Weekly. Unsubscribe anytime.